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Objective: To determine the frequency of non-alcoholic fatty liver 
in individuals with not known history of liver disease, who died 
instantly in a traffic accident. 
Materials and Methods: It was a prospective and cross-sectional 
study of a series of autopsy cases, with a convenience sample 
obtained from the forensic medical service in the municipality of 
Boca del Río, Mexico, during the period from January to December 
2016. The variables studied included age, sex, weight, height, 
abdominal circumference, thickness of the adipose panicle, cause 
of death and findings of liver biopsy.
Results:  A 78.1% of the 32 cases studied were men. The average 
age was 48 years old (range 20-80 years old). The body mass index 
range was 17-33. 34% of the cases had fatty liver. 27.3% of cases 
with fatty liver had a normal body mass index.
Conclusions: This postmortem study showed a higher frequency 
of asymptomatic hepatic steatosis than previously reported in the 
Mexican population. It is necessary to establish timely national 
measures to detect and to prevent complications of this disease.
Key words: Non-alcoholic fatty liver disease; obesity; autopsy.
Resumen
Objetivo: Determinar la frecuencia de hígado graso no alcohólico 
en individuos sin antecedentes conocidos de enfermedad hepática, 
que murieron instantáneamente en un accidente de tráfico. 
Materiales y Métodos: Fue un estudio prospectivo y transversal, 
de una serie de casos de autopsia, con una muestra por conveniencia 
obtenida en el servicio médico forense en el municipio de Boca 
del Río, México, durante el período de enero a diciembre de 2016. 
Las variables estudiadas incluyeron edad, sexo, peso, altura, 
perímetro abdominal, grosor del panículo adiposo, causa de muerte 
y hallazgos de la biopsia hepática. 
Resultados: De los 32 casos estudiados, el 78,1% eran hombres. 
La edad promedio fue de 48 años (rango 20-80 años). El rango del 
índice de masa corporal fue de 17-33. Un 34% de los casos tenían 
hígado graso. El 27.3% de los casos con hígado graso tenían un 
índice de masa corporal normal. 
Conclusiones: Este estudio postmortem mostró una frecuencia 
más alta de esteatosis hepática asintomática que la reportada 
previamente en la población mexicana. Es necesario establecer 
medidas nacionales oportunas para detectar y prevenir 
complicaciones de esta enfermedad.
Palabras clave: Esteatosis hepática no alcohólica; obesidad; 
autopsia; mexicanos.
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Introduction
Obesity has become a worldwide epidemic and it has nearly 
tripled since 1975. According to data from the World Health 
Organization (WHO), in 2016, more than 1.9 billion adults, 
18 year old and older, were overweight. Over 650 million 
of these were obese1. Obesity and overweight together 
according to the National Institutes of Health are the second 
leading cause of preventable death in the United States2.
Obesity prevalence has increased progressively since the 
1980s in Mexico. Obesity affects actually over 30% of 
the adult population3. By 2050, more people will be obese 
than overweight and there will be 12 million cumulative 
incidence cases of diabetes and 8 million cumulative incidence 
cases of heart disease3. In this country, there is a global 
average of 38% overweight (defined as body mass index 
(BMI) > 25 kg / m2), and 21 % obesity (BMI > 30 kg / m2). 
The prevalence of overweight is higher in men (41.1 %) 
than in women (35.6%), while the prevalence of obesity is 
inverse, higher in women (21.5%) than in men (14.9%)4.
On the other hand, chronic liver disease has several 
etiologies. The main etiology worldwide is chronic alcohol 
abuse, followed by viral hepatitis and nonalcoholic fatty 
liver disease (NAFLD) 5. NAFLD includes simple steatosis, 
non-alcoholic steatohepatitis (NASH) and NAFLD induced 
cirrhosis. The epidemiology of NAFLD is usually parallel to 
the prevalence of obesity, but a percentage of patients have 
normal body mass index (BMI)6. In Korea, the prevalence 
of <NAFLD< increased from 18.6% in 1998-2001 to 21.5% 
in 2016-2017 (almost 3%)7. NAFLD increased from 20.0% 
(1988-1994) to 31.9% (2013-2016) (almost 12%)8 in USA. 
In general terms, NAFLD affects 25.24% of the world 
population9.
NAFLD is characterized by an accumulation of lipids in 
the form of triglycerides (steatosis) in the liver parenchyma 
(≥ 5%), in the absence of excessive alcohol intake 
(< 20 g / day) or other chronic liver diseases and it is 
considered as expression in the liver of the metabolic 
syndrome9. The diagnosis of NASH requires the exclusion 
of other liver diseases, such as alcoholic liver disease, viral 
hepatitis and Wilson disease6. The exact prevalence of NASH 
in the general population is unknown.
A study in young individuals with overweight or obesity 
(37.1 years old, ± 13.5) performed in Mexico showed 
that 57% (290/505) of the studied population was at risk 
for nonalcoholic steatohepatitis10. Non-alcoholic hepatic 
steatosis is the most frequent cause of chronic alterations in 
liver function tests in asymptomatic individuals10.
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Some models predict that if the epidemic of obesity and 
diabetes mellitus continues like now, NAFLD and NASH 
prevalence will increase, especially NASH, with a calculated 
increase of 15-56%11.
Therefore, the objective of this postmortem study was to 
determine the frequency of hepatic steatosis/hepatitis in a 
case series of apparently asymptomatic individuals who died 
suddenly due to traffic accidents without previous report 
of liver disease. The study of this sample could provide a 
clearer idea of the frequency of liver morphological changes 
in asymptomatic subjects.
Materials and Methods
The protocol was reviewed and approved by the responsible 
Institution. 
Autopsies were performed at the Coroner’s Office, 
Municipality of Boca del Río, Veracruz, Mexico, during 
January to December 2016. It was a convenience sample that 
ultimately included 32 forensic cases.  
Inclusion criteria. The corpses of individuals, 16-year-old 
and older, with eight or less hours since declared death in a 
traffic accident, were included. 
Exclusion criteria. Excluded cases were those with 
macroscopic liver damage, a known background of viral or 
chronic liver disease, alcoholism, and positive toxicological 
tests for alcohol and/ or drugs of abuse.
The variables studied included age, sex, weight, height, 
abdominal perimeter, fat panicle thickness and direct cause 
of death. The thickness of the adipose panicle was measured 
in situ at the level of the lower border of the umbilical scar, 
once the longitudinal incision for the autopsy had been made.
After measuring and weighing the liver, two1x1x1 cm, wedge 
biopsies were performed wedge biopsies corresponding to 
the lateral segment of left lobe and posterior segment of right 
lobe; subsequently, they were fixed with 4% buffered formalin 
for 24 hours. Hematoxylin & eosin and Masson’s trichrome 
stains were performed, and biopsies were analyzed with a 
light microscope by a certified pathologist according to the 
NASH CRN Scoring System table 1; with this score system, 
a NAS score of ≥ 5 correlates with a diagnosis of ‘‘definite 
NASH’’ whereas NAS ≤3 correlates with a diagnosis of ‘‘not 
NASH12.
Ethical considerations: This study does not include personal 
data. Forensic autopsies do not require authorization from 
family members and they are carried out at the request of 
the State, represented by the prosecuting attorney according 
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to the Code of Criminal Procedures and the General Law of 
Health; however, the protocol was registered at the General 
Attorney, which approved the study and sampling.
Results
During the period from May 4, 2016 to November 15, 
2016, 32 cases that met the inclusion criteria previously 
discussed were documented and collected. All deaths were 
instantaneous. The toxicological test ruled out recent drugs 
or alcohol intake.
78.1% of the 32 cases studied, (n=25) were males and 21.8% 
(n=7) were females. The average age was 48 years old with 
a range of 20-80 years old table 2.
The body mass index (BMI) range was 17-33; no grade II-
IV obesity was observed. The abdominal perimeter ranged 
between 60-95 cm.
The thickness range of the adipose panicle was 1-7 cm, 
with the following distribution according to weight: normal 
weight, 1-4 cm (mode=2); overweight, 3-7 cm (mode= 6), 
and grade I obesity, 5-7 cm (mode= 5).The weight of the 
liver had a range of 1300 to 1850 g table 3.
The study of cases with low or normal BMI, without 
steatosis, showed that of 14 cases with normal histology, 
one (7.1%) was a woman with low IBM and 13 (92.9%) had 
normal IBM.Two of these were women and 11 were men. 
The women in this group had a liver weight of 1300 and 
1500 g, with an average of 1416 g. In the group of men, the 
range was between 1100-1700 g with an average of 1531 g.
Finding in cases with overweight / obesity, without steatosis, 
were as follows: There were seven cases, 71.4% (n=5) men 
and 28.6 % (n=2) woman. The liver weight range in men was 
1575-1850 g, while the overweight woman had a liver of 
1700 g. There was also a woman with grade I obesity (liver, 
1650 g).
Table 1. NASH CRN Scoring System: NAS and Fibrosis Score
Steatosis Grade Lobular Inflammation
Hepatocellular 
Ballooning Fibrosis Score
D* (%) D F** D F D F
0 <5% 0 None 0 None 0 None
1 5-33 1 <2 foci/20x optical field 1 Mild, few 1a
Mild (delicate) zone 3 
perisinusoidal fibrosis
1b Moderate (dense) zone 3 perisinusoidal fibrosis




1c Portal/periportal fibrosis only
2
Zone 3 perisinusoidal 
fibrosis with portal/
periportal fibrosis
3 >66 3 >4 foci/20x optical field 3 Bridging fibrosis
4 Cirrhosis
Source: According to Puri and Sanyal12 D*: Degree   F**: Findings
NAS: Nonalcoholic fatty liver disease activity score
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37 F 1500 72 3 23.3 NL 0 0
75 F 1650 95 5 33.0 O-I 0 0
65 M 1450 82 2 23.8 NL 0 0
25 M 1740 80 3 27.0 OW 0 0
23 M 1450 78 4 20.55 NL 0 0
36 F 1700 90 6 25.9 OW 0 0
58 M 1100 64 1 24.98 NL 0 0
55 M 1750 89 3 27.68 OW 1 0
35 M 1700 72 2 23.66 NL 0 0
38 M 1450 80 5 31.89 O-I 2 1
29 M 1500 65 3 25.71 OW 3 1
48 M 1600 78 5 25.95 OW 1 0
32 M 1450 68 4 22.23 NL 0 0
84 M 1650 72 3 23.03 NL 0 0
67 M 1700 87 6 28.34 OW 0 0
71 M 1450 72 2 19.84 NL 0 0
47 M 1850 84 7 29.07 OW 0 0
72 M 1650 70 2 19.84 NL 0 0
40 F 1450 60 4 19.81 NL 0 0
20 F 1300 60 2 17.36 LW 0 0
33 M 1650 86 4 27.36 OW 0 0
67 M 1575 89 4 25.06 OW 0 0
65 M 1650 70 2 22.31 NL 0 0
44 M 1750 72 2 23.53 NL 1 0
35 M 1780 92 6 28.09 OW 1 0
85 M 1650 80 6 27.44 OW 1 0
62 M 1700 69 2 22.49 NL 0 0
46 F 1600 79 7 31.25 O-I 3 1
28 M 1600 80 3 23.39 NL 0 0
56 M 1450 78 3 24.00 NL 1 0
25 F 1450 71 7 24.09 NL 3 1
31 M 1750 89 6 29.07 OW 1 0
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Table 2. Age, sex, BMI and abdominal perimeter.
Source: Own data
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37 F 1500 72 3 23.3 NL 0 0
75 F 1650 95 5 33.0 O-I 0 0
65 M 1450 82 2 23.8 NL 0 0
25 M 1740 80 3 27.0 OW 0 0
23 M 1450 78 4 20.55 NL 0 0
36 F 1700 90 6 25.9 OW 0 0
58 M 1100 64 1 24.98 NL 0 0
55 M 1750 89 3 27.68 OW 1 0
35 M 1700 72 2 23.66 NL 0 0
38 M 1450 80 5 31.89 O-I 2 1
29 M 1500 65 3 25.71 OW 3 1
48 M 1600 78 5 25.95 OW 1 0
32 M 1450 68 4 22.23 NL 0 0
84 M 1650 72 3 23.03 NL 0 0
67 M 1700 87 6 28.34 OW 0 0
71 M 1450 72 2 19.84 NL 0 0
47 M 1850 84 7 29.07 OW 0 0
72 M 1650 70 2 19.84 NL 0 0
40 F 1450 60 4 19.81 NL 0 0
20 F 1300 60 2 17.36 LW 0 0
33 M 1650 86 4 27.36 OW 0 0
67 M 1575 89 4 25.06 OW 0 0
65 M 1650 70 2 22.31 NL 0 0
44 M 1750 72 2 23.53 NL 1 0
35 M 1780 92 6 28.09 OW 1 0
85 M 1650 80 6 27.44 OW 1 0
62 M 1700 69 2 22.49 NL 0 0
46 F 1600 79 7 31.25 O-I 3 1
28 M 1600 80 3 23.39 NL 0 0
56 M 1450 78 3 24.00 NL 1 0
25 F 1450 71 7 24.09 NL 3 1
31 M 1750 89 6 29.07 OW 1 0
Source: Own data
A: Age; Sx: Sex; AP: adipose panicle; ST: Steatosis; I: Inflammation. BMI (body mass in-
dex);  NL: normal; OW: overweight; OB-I: Obesity grade I.
ri t  sanit ri   /  l. , . ,  - August 2
htt :// t . j t. /
Original Article Frequency of non-alcoholic fatty liver disease in forensic cases 
173
Horizonte sanitario  /  vol. 20, no. 2, mayo - agosto 2021
http://revistas.ujat.mx/index.php/horizonte
In liver biopsies, fibrosis and ballooning degeneration of 
hepatocytes were not documented, and steatosis grades 1-3, 
was observed figure 1. Of the 32 cases studied, 34% (n=11) 
presented steatosis table 3. The distribution of steatosis 
by grade was as follows: grade I, 7 cases; grade 2, 1 case, 
and grade 3, 3 cases. In 12.5% (n=4), mild inflammation 
was observed that coincided with the three cases of grade 
3-steatosis, and the case of grade 2-steatosis. With a 
maximum score of 4, the steatohepatitis activity in this 
sample was “indeterminate”.
Discussion
Non‐alcoholic fatty liver disease (NAFLD) is a complex 
entity characterized by steatosis, and it can progress to 
nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately 
hepatocellular carcinoma13,14.
NAFLD is associated with obesity and metabolic syndrome. 
Hepatic steatosis is related to body adiposity, especially 
central obesity15. However, in this study, central obesity was 
found only in a 36-years-old, over-weight women with 90 
cm of abdominal circumference and in 75-years-old women 
with obesity grade I, and abdominal circumference of 95 cm. 
Neither one had hepatic steatosis.
Figure 1. Liver biopsy. Woman, 25 years old with normal BMI, liver weight of 1450 g and  
steatosis grade 3 with mild inflammation (arrow) (H&E, A, 100 X and B, 400 X). 
In the other hand, the thickness of the adipose panicle 
appeared to be related to the increase in body weight, in 
such a way that no corpses of subject with normal IBM 
had more than 4 cm of adipose panicle. In overweight and 
obesity grade I subjects, the maximum thickness was 7 cm. 
There is a relationship between obesity as cause of death and 
increased thickness of adipose panicle for values between 
8.5 and 9.5 cm16.
The liver is about 2% of the weight of an adult17. Livers in 
this study weighed between 1.6 and 2.9% of body weight. 
The corps with livers corresponding to 2.7-2.9% of body 
weight, had normal or low body weight. Therefore, it is 
feasible to observe even grade 3-steatosis in subjects with a 
normal BMI and an adequate liver weight. In fact, in some 
forensic studies, liver steatosis has been detected in 15% 
of non-obese subjects, in 65% of obese ones and in 85% of 
those with morbid obesity18.
According to NAFLD Activity Score12,19, a score of ≥ 5 
NASH is required to diagnose steatohepatitis. In this sample, 
steatosis was very frequent (34.4%). However, although 
in 12.5%, mild inflammation was observed, the score was 
not enough to diagnose hepatitis. If we realize that these 
individuals were clinically asymptomatic and were mostly 
only overweight, the findings are worrisome. All the cases 
with liver inflammation had steatosis and one subject had 
normal weight, one was overweight and two had obesity 
grade I. However, although in 12.5%, mild inflammation was 
observed, the score was not enough to diagnose hepatitis in 
these cases. Therefore, having a patient with a normal body 
mass index does not rule out the possibility of having a fatty 
liver disease.
Source: Own data
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There is a wide variability for the development of fatty liver, 
favored among other things, by genetic polymorphisms 
combined with other factors such as excess intake of calories, 
high-fructose syrup beverage consumption and lack of 
exercise20.
 
These polymorphisms include the I148M PNPLA3 variant 
21 as well as the TM6SF2, MBOAT7 and GCKR genes21,22. 
The isoleucine to methionine substitution at position 148 in 
the patatin-like phospholipase domain containing 3-protein 
(PNPLA3 gene; I148M variant) is associated with steatosis and 
an increased risk of chronic liver disease ranging from hepatitis 
to hepatocellular carcinoma21. Carriers of the PNPLA3 gene 
variant develop an excess of adiposity in childhood and are at 
higher risk of developing fatty liver23.
Genetic variant TM6SF2 E167K induces increased hepatocyte 
fat content by reducing circulating apolipoprotein B100 
levels22. Also, rs641738 C>T variant in the locus that contains 
the membrane bound O-acyltransferase domain-containing 
7 gene (MBOAT7, also called LPIAT1) is associated with 
lower protein expression in the liver and changes in plasma 
phosphatidylinositol species24. It seems to be an association 
between the MBOAT7 rs641738 gene variant and the 
development and severity of NAFLD in individuals of European 
descent24.
A Mexican study reported that PNPLA3, LYPLAL1, GCKR 
and PPP1R3B polymorphisms were associated with higher 
triglyceride content in the liver25. The study of these variants in 
subjects with steatosis would highlight those individuals with a 
higher risk of evolving to steatohepatitis.
Most studies of the prevalence of NAFLD have been performed 
using ultrasonography (US), computed tomography or magnetic 
resonance spectroscopy methods26. In spite of recent advances, 
histology remains the gold standard for diagnosis of NAFLD; 
therefore, this postmortem study provided valuable material of 
asymptomatic subjects, impossible to obtain by other means.
The prevalence of NAFLD in the general population is very 
variable. It affects 30% of the United States of America 
population27. In Iran, NAFLD prevalence in 116 cases of young 
cadaveric organ donors was 13% and 80% had mild hepatic 
steatosis28.
In 2006, two different US studies in asymptomatic Mexican 
population showed a NAFLD prevalence of 15.7-17%29,30. 
Although, this postmortem preliminary study is limited by the 
size of the sample, the lack of genetic polymorphisms analysis 
and of liver functional tests, it found that the percentage of 
asymptomatic subjects affected by steatosis is higher than 
that reported in previous studies in Mexican population29,30. 
Furthermore, 27.3% of the cases with NAFLD had a normal 
BMI. Public policies based on population education and the 
abolition of junk food production are required. A reduction 
in both, high-fructose syrup beverage production and 
consumption in individuals of all ages should be sought31. It 
has been proven in animal models that, these beverages are 
metabolized to glyceraldehyde (GA) in the liver and GA-
derived advanced glycation end-products are generated and 
may induce the onset/progression of non-alcoholic fatty liver 
disease31. In the same way the increase in physical activity 
and the promotion of healthy and balanced food should be 
part of public health policies. Returning to the milpa diet32 
- the healthy eating model of Mesoamerican origin, which 
has milpa products (corn, beans, chili and squash) as its 
nutritional center is a nutritionally balanced option and 
bring drinking water to all communities must be part of the 
strategies to combat this growing pathology.
Conclusions
The 34 % of subjects without symptoms of liver disease, who 
died in traffic accidents, had hepatic steatosis. This suggests 
that the problem of silent steatosis in Mexico, is greater 
than previously thought and requires the establishment of 
national timely measures to prevent it and to detect early 
complications.
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